[Complications in a patient with liver cirrhosis and HCV coinfection during treatment with peginterferon and ribavirin].
Authors present a case of 15-years old girl with liver cirrhosis due to biliary atresia with HCV coinfection with portal hypertension after several episodes of variceal bleeding treated primarily with sclerotherapy and later with transjugular intrahepatic porto-systemic stent shunt. In a patient during the combined peginterferon alfa-2b and ribavirin treatment a decompensation of liver occurred with necessity for liver transplantation.
Pawłowska
Joanna
J
Klinika Gastrologii, Hepatologii i Immunologii IP-CZD. liver@czd.waw.pl
Sokal
Etienne
E
Jankowska
Irena
I
Teisseyre
Mikołaj
M
Rokitka
Maria
M
Socha
Jerzy
J
D000293:Adolescent; D000998:Antiviral Agents / Q000009:adverse effects*; D001656:Biliary Atresia / Q000150:complications; D002648:Child; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D006975:Hypertension, Portal / Q000150:complications; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008103:Liver Cirrhosis / Q000150:complications* / Q000188:drug therapy* / Q000209:etiology; D017093:Liver Failure / Q000209:etiology* / Q000601:surgery; D016031:Liver Transplantation; D011092:Polyethylene Glycols; D019168:Portasystemic Shunt, Transjugular Intrahepatic; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b